Omnes Capital's investments

Sector 
Hardware
Entry Date 
2018
Business 
Venture Capital

Mipsology

French start-up at the forefront of Deep Learning
Founded in 2015, the start-up has developed software, Zebra, which can perform the billions of calculations necessary to carry out the "neural networks" used in Deep Learning. Artificial Intelligence (AI) applications such as robot and quality control in industry, facial recognition, cancer detection from imagery or driver assistance, all rely on neural networks to model unstructured information often linked to Big Data.
Entry Date 
2018
Business 
Venture Capital

Pherecydes Pharma

Specializes in research into innovative and adaptive solutions to fight multi-resistant bacterial infections

Pherecydes Pharma SA specializes in research into innovative and adaptive solutions to fight multi-resistant bacterial infections, using cocktails of natural phages.  
Thanks to its unique expertise, Pherecydes Pharma has managed to develop a large bank of bacteriophages cocktails to fight antibiotic-resistant infections, steadily on the rise since the 1980s.

Sector 
Pharma
Entry Date 
2017
Business 
Venture Capital

Octimet

Development of a clinically de-risked MET kinase inhibitor for the treatment of cancers

Founded in 2016, Octimet Oncology N.V. (Belgium) is a new company (spin-off from Johnson & Johnson) that acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset 0MO-2 will also enter the portfolio.

Sector 
SaaS / Cloud
Entry Date 
2013
Business 
Venture Capital

European Games Group

Video games company dedicated to independent developers without the financial clout to maximise their marketing efforts

The company specialises in monetising and marketing cross-platform video games that run on mobiles, tablets, Facebook or web browsers. The company has built up a substantial portfolio of games, including the highly popular Hero Zero by developer Playata. Hero Zero has signed up more than 17 million users and ranked as the eighth most searched-for game in Brazil during 2013, coming in ahead of AAA titles such as PES 2014.

Sector 
SaaS / Cloud
Entry Date 
2012
Business 
Venture Capital

Greenbureau

Digital customer relationship specialist.

Greenbureau is the first free-of-charge confidential and secure internet service that centralises bills for consumers. A pioneer of multi-brand digital customer relationships, Greenbureau saves on running costs for large groups by switching their customers over to digital billing, invoicing and online account management, etc.

Sector 
Mobile
Entry Date 
2012
Business 
Venture Capital

Tree Digital Factory

Mobile advertising network

Mister Bell joind the Tree Digital Factory Group.

Mister Bell is a mobile performance based mobile advertising network founded in 2010.
With an exclusive inventory and unprecedented distribution capacity, Mister Bell is establishing itself as one of the leaders in mobile performance in Europe, Latin America and the Middle East. With its proprietary advertising tracking and re-targeting systems on smartphones and tablets, Mister Bell guarantees ROI levels to advertisers and offers innovative monetisation systems to content providers. Mister Bell is headquartered in Paris and now has subsidiaries in London, Berlin and Rio.

 

Sector 
SaaS / Cloud
Entry Date 
2012
Business 
Venture Capital

Progexia

An alternative operator serving private health insurance companies

Progexia is an alternative operator serving private health insurance companies, wich provide solutions in the Cloud for reduce benefits payments costs.

Sector 
Medical devices
Entry Date 
2011
Business 
Venture Capital

Pixium

Up-and-coming leader in bionic vision and vision restoration systems (VRS)

Pixium Vision was founded in December 2011 by Bernard Gilly, Professor José-Alain Sahel, and several highly renowned scientists from prestigious academic and technology institutions. The company develops innovative vision restoration systems (VRS) that are active medical devices. They can be implanted to treat blindness caused by degeneration of the photo-receptor cells of the retina. VRS stimulate the retina to produce a bionic vision and aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Called IRIS® (in clinical trials) and PRIMA (under development), these VRS harness the latest advances in microelectronics/nanoelectronics, optronics, neurobiology and software. With the help of these technologies, Pixium Vision ultimately aims to provide a therapeutic solution delivering bionic vision as close as possible to normal vision.

“Within ten years, we can become the world leader in the market.”
BERNARD
GILLY
Executive Chairman
of Pixium Vision
Pixium Vision

A long-term view

In June 2014, Omnes Capital supported the initial public offering made by Pixium Vision, a start-up specialising in vision restoration systems (VRSs). The IPO was highly successful, as one would expect for a company at the leading edge of research into visual impairment. A month later, Bernard Gilly, head of Pixium Vision, confirmed its success, with a total of €39.5 million ultimately raised.
BERNARD GILLY
Executive Chairman of Pixium Vision

Disruptive innovation

Alexia Perouse (Partner at Omnes Capital) and Bernard Gilly first discussed vision restoration systems in the early 2000s. "VRSs aim to enable blind people to perceive shapes and movements, a really tremendous project. But their design came up against two hurdles, systems miniaturisation and real-time image transmission", explains Bernard Gilly. 

 

Pixium overcame these hurdles in 2011 when it launched IRIS (short for Intelligent Retinal Implant System), consisting of a pair of glasses with an integrated mini-camera linked to a pocket computer and a retinal implant that stimulates the brain cells. 

 

"It met all our criteria for investment: disruptive technology, a seasoned management team and a promising medtech sector", says Alexia Perouse. So in 2012, Omnes Capital invested €5 million.

BERNARD
GILLY
Executive Chairman
of Pixium Vision
What sets Pixium apart from its competitors?
Our technology. We are pioneers in VRSs working as artificial retinas. IRIS, our first implant, has between 50 and 150 electrodes and can be implanted under general anaesthetic in two hours. PRIMA, the next generation, will have more than one thousand wireless electrodes and will be implanted under local anaesthetic in just 30 minutes. Both are being developed by an international network of research scientists from the Vision Institute, Université Pierre-et- Marie-Curie and the universities of Stanford and Jerusalem.
What do you expect from your partnership with Omnes Capital?
Omnes Capital has always been a partner that assesses our decisions, our strategy and our new hires, such as Pierre Kemula (former head of Investor Relations at Ipsen) who joined us as CFO last June. Alexia Perouse and her team know our project intimately, as they do the biotechnology and medical devices markets in general. We are united by strong mutual trust, which also stems from our long-standing relationship with Alexia, whom I have known since 2000.
What are your ambitions for the next few years?
The market is structuring itself. Within ten years, we can become a world leader with IRIS and PRIMA, but also with our R&D work on optical nerve pathologies, such as glaucoma. Will this growth be achieved alone or as part of a major group following a buyout? Only time will tell.

Timeline

• 2011: Bernard Gilly founds Pixium Vision with a group of scientists working at the Vision Institute and Université Pierre-et-Marie-Curie
• 2012: The first funding round organised with Omnes Capital raises €23.5 million
• 2013: Clinical trials begin on IRIS
• 2014: The IPO raises €39.5 million
• 2015: Development of IRIS begins in the United-States
pixium-vision
Sector 
SaaS / Cloud
Entry Date 
2011
Business 
Venture Capital

viavoo

Software suite in SaaS mode providing semantic analysis of interactions

A SaaS developer, viavoo can provide real-time analysis of consumer feedback to gain insight into their online or point-of-sale shopping experience, their views about products and services or about after-sales service, etc.
Operating across multiple channels (email, chat, satisfaction surveys, blogs, forums, opinions, social media), the linguistic technology developed by viavoo provides results very close to human understanding and can identify situations, questions, opinions, suggestions, intentions and complaints in customer feedback.
The data collected by viavoo is intended to provide marketing and customer relationship insights that help to use the customer’s own voice to improve customer experience, differentiation, loyalty and retention.

 

Sector 
SaaS / Cloud
Entry Date 
2011
Business 
Venture Capital

Trusted Shops

European leader in subscription-based certification of online retailers

Founded in 1999 and headquartered in Germany, the company audits online stores applying a set of over 100 criteria, such as solvency, price transparency, customer service and personal data protection. After a successful audit, Trusted Shops issues the Trust Badge seal of approval and provides the option of a guarantee for shoppers. Today, more than 20,000 ecommerce sites across Europe display the seal of approval and over 10 million purchases have been protected by the money-back guarantee.

Pages

NewsRoom
Press release
25 November 2019
Omnes welcomes on board two new Analysts
Omnes welcomes on board two new Analysts
Press release
20 November 2019
TISSIUM Closes €39M Series B Funding Round
TISSIUM Closes €39M Series B Funding Round
Publication
Table ronde à LP/GP : les clés de la relation. A lire dans le Magazine des Affaires avec la participation d'Omnes (avril 2019)
Press release
28 October 2019
Solvionic completes a €4 million funding round from Omnes and IRDI Soridec
Solvionic completes a €4 million funding round from Omnes and IRDI Soridec
Press release
08 October 2019
Omnes invests in Biosyl as part of a sponsorless deal
Omnes invests in Biosyl as part of a sponsorless deal
Press release
01 October 2019
Glennmont purchases 211MW unsubsidised Finnish wind project from Ilmatar Energy
Glennmont purchases 211MW unsubsidised Finnish wind project from Ilmatar Energy

Pages